Predict your next investment

HEALTHCARE | Drug Development
combimatrix.com

See what CB Insights has to offer

Executives

11

Board of Directors

4

CombiMatrix Board of Directors

4 Board of directors

CombiMatrix has 4 board of directors, including Dirk van den Boom.

Name

Firm

Work History

Other Seats

Dirk van den Boom

Innovative and versatile CEO with a progressive career history in the Life Sciences/Diagnostics industry. A visionary leader with a passion for developing new technologies to revolutionize medical practices for physicians and their patients. Extensive knowledge and expertise across clinical research, product development, and commercialization. Diplomatic with high moral standards and a driven work ethic to inspire and motivate top-performing teams. Co-author on over 95 peer-reviewed publications and inventor on more than 80 patents/ patent applications.

CombiMatrix

Martin Felsenthal

Martin R. Felsenthal is a Partner of HLM Venture Partners. Marty was previously a General Partner of Salix Ventures, where he focused on investments in health care services and health care information technology. Marty served on the boards of Vantage Oncology, US Renal Care, Ancillary Care Management, Vericare, AccentCare, Titan Health and Payerpath. At Salix, Marty was involved in helping management found a number of new businesses through platform acquisitions, including Vantage and Vericare. He also recruited more than 25 executives to the portfolio companies with whom he worked. He is currently a director of Aperio Technologies and Vericare Management and a board observer at Vantage Oncology. Marty also serves on the Board of the Northern California Chapter of the Crohn's and Colitis Foundation of America. He received a BA from Princeton University and an MBA from the Stanford University Graduate School of Business.

CombiMatrix

Scott Gottlieb

Most recently, Dr. Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administra­tion (FDA) from 2017 to 2019. Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors including serving as Managing Director, T.R. Winston & Company from 2013 to 2017. Dr. Gottlieb was previously the FDA’s Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as the senior advisor to the FDA Commissioner from 2003 to 2004. Dr. Gottlieb is a member of the National Academy of Medicine and is a Contributor to the financial news network, CNBC. He also serves on the boards for Pfizer, Illumina, Aetion, and Tempus.

CombiMatrix

Thomas Akin

CombiMatrix

Name

Dirk van den Boom

Martin Felsenthal

Scott Gottlieb

Thomas Akin

Firm

Work History

Innovative and versatile CEO with a progressive career history in the Life Sciences/Diagnostics industry. A visionary leader with a passion for developing new technologies to revolutionize medical practices for physicians and their patients. Extensive knowledge and expertise across clinical research, product development, and commercialization. Diplomatic with high moral standards and a driven work ethic to inspire and motivate top-performing teams. Co-author on over 95 peer-reviewed publications and inventor on more than 80 patents/ patent applications.

Martin R. Felsenthal is a Partner of HLM Venture Partners. Marty was previously a General Partner of Salix Ventures, where he focused on investments in health care services and health care information technology. Marty served on the boards of Vantage Oncology, US Renal Care, Ancillary Care Management, Vericare, AccentCare, Titan Health and Payerpath. At Salix, Marty was involved in helping management found a number of new businesses through platform acquisitions, including Vantage and Vericare. He also recruited more than 25 executives to the portfolio companies with whom he worked. He is currently a director of Aperio Technologies and Vericare Management and a board observer at Vantage Oncology. Marty also serves on the Board of the Northern California Chapter of the Crohn's and Colitis Foundation of America. He received a BA from Princeton University and an MBA from the Stanford University Graduate School of Business.

Most recently, Dr. Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administra­tion (FDA) from 2017 to 2019. Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors including serving as Managing Director, T.R. Winston & Company from 2013 to 2017. Dr. Gottlieb was previously the FDA’s Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as the senior advisor to the FDA Commissioner from 2003 to 2004. Dr. Gottlieb is a member of the National Academy of Medicine and is a Contributor to the financial news network, CNBC. He also serves on the boards for Pfizer, Illumina, Aetion, and Tempus.

Other Seats

CombiMatrix

CombiMatrix

CombiMatrix

CombiMatrix

CombiMatrix Management Team

11 Team Members

CombiMatrix has 11 executives. CombiMatrix's current Chief Technology Officer is Donald D Montgomery.

Name

Work History

Title

Status

Donald D Montgomery

Chief Technology Officer

Current

Warren G Hargis

Senior Vice President

Current

Jeffrey B Oster

Senior Vice President

Current

Gerald D Knudson

Chief Executive Officer

Former

Amit Kumar

Chief Executive Officer

Former

Name

Donald D Montgomery

Warren G Hargis

Jeffrey B Oster

Gerald D Knudson

Amit Kumar

Work History

Title

Chief Technology Officer

Senior Vice President

Senior Vice President

Chief Executive Officer

Chief Executive Officer

Status

Current

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.